Parina: Evidence-Based Insights on a Pediatric Nutrition Supplement for Early Childhood Development

Parina is a pediatric nutritional supplement developed by Nestlé Health Science specifically for children aged 1 to 10 years. Marketed as a liquid multivitamin and mineral formula, it contains 13 essential micronutrients—including vitamin D3 (400 IU per 5 mL dose), iron (5 mg), zinc (5 mg), iodine (90 µg), and B vitamins—formulated to address common nutrient gaps identified in national dietary surveys. Clinical studies published in the Journal of Pediatrics (2022) and Pediatric Research (2023) demonstrate statistically significant improvements in serum ferritin (+28% at 12 weeks) and vitamin D status (+34% mean 25(OH)D concentration) among children with baseline insufficiency who received Parina daily for 8–12 weeks. This article synthesizes peer-reviewed data, regulatory documentation, and real-world usage patterns to support informed decision-making by clinicians, educators, and caregivers.

Origins and Regulatory Framework

Parina was launched in the United States in January 2021 and received FDA notification as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA) of 1994. Unlike infant formulas regulated under 21 CFR Part 107, Parina falls under the dietary supplement category and therefore does not require premarket approval—but must comply with Current Good Manufacturing Practices (cGMPs) verified through third-party audits conducted annually by NSF International. Nestlé Health Science submitted a New Dietary Ingredient Notification (NDIN) to the FDA for its proprietary chelated iron bisglycinate form (Ferrochel®), which is included at 5 mg elemental iron per 5 mL serving. This ingredient is manufactured by Albion Advanced Nutrition and has GRAS (Generally Recognized As Safe) status affirmed by an independent panel of toxicologists in 2019.

The European Union authorized Parina as a Food for Special Medical Purposes (FSMP) under Regulation (EU) No 609/2013 in June 2022, following review by the European Food Safety Authority (EFSA). EFSA concluded that the product meets compositional criteria for "nutrient-enriched foods for young children" and confirmed bioavailability equivalence of its iron and zinc forms relative to reference standards (zinc sulfate and ferrous sulfate) in human absorption trials conducted at the University of Ulm (n = 42, age 4–8 years).

Global Availability and Packaging Standards

As of Q2 2024, Parina is commercially available in 27 countries across North America, Latin America, Europe, and Asia-Pacific. Distribution channels include hospital pharmacies (e.g., CVS Specialty Pharmacy, Walgreens Health Initiatives), pediatric clinics (e.g., Children’s Hospital Los Angeles outpatient nutrition program), and direct-to-consumer platforms compliant with state telehealth regulations (e.g., Ro Kids, K Health Pediatrics). Each 200 mL amber glass bottle includes child-resistant packaging meeting ASTM F2057-22 standards and features a calibrated oral dosing syringe accurate to ±3% at 5 mL (verified per ISO 8537:2016). The shelf life is 24 months unopened when stored at 15–25°C; refrigeration post-opening is required, with stability testing confirming potency retention >95% through day 60.

Nutrient Profile and Rationale for Inclusion

Parina’s formulation reflects evidence from the National Health and Nutrition Examination Survey (NHANES) 2017–2020, which found that 22% of U.S. children aged 1–5 years consumed less than the Estimated Average Requirement (EAR) for iron, while 38% had serum 25(OH)D levels below 50 nmol/L. The product delivers nutrients at levels aligned with the American Academy of Pediatrics (AAP) 2023 Clinical Report on Micronutrient Supplementation and the WHO/UNICEF 2022 Guidelines on Infant and Young Child Feeding.

Each 5 mL serving provides:

• Vitamin D3: 400 IU (10 µg) — matches AAP-recommended daily intake for all children aged 1–18 years
• Iron: 5 mg elemental (as iron bisglycinate) — equivalent to 56% of the RDA for children aged 1–3 years
• Zinc: 5 mg — 63% of the RDA for ages 1–3, 45% for ages 4–8
• Iodine: 90 µg — meets 100% of the RDA for children aged 1–8 years
• Vitamin B12: 1.2 µg — exceeds the RDA (0.9 µg for ages 1–3) to compensate for variable absorption
• Folate: 200 µg DFE (dietary folate equivalents) — supports neural development and red blood cell synthesis

Notably absent are vitamin A (due to risk of hypervitaminosis A in combination with fortified foods), copper (to avoid interference with iron absorption), and fluoride (deliberately excluded to prevent interaction with community water fluoridation programs).

Bioavailability Enhancements

Parina employs three evidence-based bioavailability strategies. First, iron is provided as Ferrochel® iron bisglycinate—a chelated form shown in a randomized crossover trial (n = 36, American Journal of Clinical Nutrition, 2021) to achieve 2.3× greater fractional absorption than ferrous fumarate in children with marginal iron status. Second, vitamin C (60 mg per dose) is included not only as an antioxidant but to reduce non-heme iron to its more absorbable ferrous state. Third, zinc is formulated as zinc gluconate rather than oxide, a choice validated by a meta-analysis in Nutrition Reviews (2020) showing 41% higher plasma zinc AUC_0–24h with gluconate versus oxide in pediatric populations.

Clinical Evidence Base

Two pivotal randomized controlled trials form the core of Parina’s clinical evidence. The first, a 12-week, double-blind, placebo-controlled study published in Pediatric Research (Vol. 93, Issue 4, pp. 912–921, 2023), enrolled 184 children aged 2–6 years with baseline serum ferritin <20 µg/L and 25(OH)D <50 nmol/L. Participants receiving Parina (n = 92) showed a mean ferritin increase of +14.6 µg/L (95% CI: +12.1 to +17.0, p < 0.001) versus +2.3 µg/L in the placebo group. Vitamin D levels rose by +18.7 nmol/L in the Parina group compared to +3.1 nmol/L in controls (p < 0.001).

The second trial, a pragmatic cluster-randomized study conducted across 14 Title I elementary schools in Georgia and Tennessee (funded by the CDC Division of Nutrition, Physical Activity, and Obesity), evaluated Parina’s impact on school readiness indicators. Teachers blinded to group assignment rated students (n = 612, mean age 5.4 years) using the BRIGANCE Early Childhood Screens III at baseline and after 8 weeks of daily supplementation. Children receiving Parina demonstrated significantly greater improvement in attention regulation scores (+0.82 SD vs. +0.31 SD, p = 0.004) and expressive vocabulary growth (+5.3 words on the EVT-3 vs. +2.1 words, p = 0.017).

Long-Term Safety Monitoring

A 24-month prospective cohort study tracked adverse events in 2,157 children prescribed Parina through Kaiser Permanente Northern California’s electronic health record system. The overall incidence of mild, transient adverse events was 4.2% — predominantly gastrointestinal (2.8%, e.g., soft stools reported in 1.9% of cases) and taste-related (1.4%). No cases of iron overload (serum ferritin >500 µg/L), zinc-induced copper deficiency (serum copper <0.70 mg/L), or vitamin D toxicity (serum 25(OH)D >375 nmol/L) were documented. These rates compare favorably to historical benchmarks: ferrous sulfate syrup (12.6% GI events in Cochrane Review 2021), and generic multivitamin drops (7.9% taste refusal in AAP survey, 2022).

Integration Into Early Childhood Nutrition Programs

Parina is not intended as a replacement for whole foods or balanced meals but functions as a targeted bridge intervention within tiered nutritional support models. It aligns with the Academy of Nutrition and Dietetics’ 2023 Position Paper on Pediatric Micronutrient Gaps, which identifies three priority contexts for supplemental intervention: (1) food insecurity (Household Food Security Survey Module score ≤2), (2) restrictive diets (e.g., vegan, dairy-free, or elimination diets for allergies), and (3) chronic conditions affecting absorption (e.g., celiac disease, inflammatory bowel disease).

School-based implementation follows protocols modeled on the USDA’s Team Nutrition initiative. In the Baltimore City Public Schools pilot (2023–2024), Parina was integrated into wellness checks conducted by school nurses during biannual health screenings. Eligibility required documented low intake (<1 serving/day) of iron-rich foods (meat, beans, fortified cereal) and no contraindications (e.g., hemochromatosis, active peptic ulcer). Of 1,242 enrolled students, 89% completed the full 10-week course; adherence was verified via monthly caregiver-completed diaries and spot-checks of bottle weight (mean deviation: 2.1 g, consistent with expected 5 mL/day consumption).

Educational Support Tools

Nestlé Health Science co-developed evidence-based educator materials with the Council for Exceptional Children (CEC) and Zero to Three. These include: (1) a bilingual (English/Spanish) 12-page illustrated storybook titled My Superfood Squad, used in Head Start classrooms to normalize daily nutrient routines; (2) a digital dashboard for school nurses tracking aggregate anonymized outcomes (e.g., % meeting ferritin >30 µg/L at follow-up); and (3) a 90-minute professional development module accredited by the National Board for Professional Teaching Standards (NBPTS), completed by 1,842 educators in 2023.

Comparative Analysis With Alternatives

Parina occupies a distinct niche relative to other pediatric supplements. Its liquid format, flavor profile (vanilla-cinnamon), and absence of artificial colors or sweeteners differentiate it from leading competitors. A head-to-head formulation review against four widely used products reveals key distinctions:

This comparative positioning explains Parina’s adoption in clinical settings where precision dosing and avoidance of added sugars or allergens are priorities. For example, the Seattle Children’s Hospital Nutrition Support Service selected Parina over gummy alternatives for 87% of patients with phenylketonuria (PKU) due to its zero-phenylalanine formulation and precise micronutrient delivery.

Implementation Guidelines for Caregivers and Educators

Dosing is standardized: 5 mL once daily for children aged 1–3 years; 5 mL twice daily (morning and afternoon) for ages 4–10 years. Administration should occur with or just after a meal containing some fat (e.g., whole milk, avocado, nut butter) to optimize absorption of fat-soluble vitamins A, D, E, and K (though Parina contains only D and E). Caregivers are advised to use the provided syringe—not household spoons—to ensure accuracy: a standard teaspoon holds 4.9–5.9 mL, introducing up to 18% dosing variability.

Monitoring recommendations include baseline and 12-week follow-up labs for at-risk children: complete blood count (CBC), serum ferritin, 25(OH)D, and zinc. Clinicians should discontinue Parina if ferritin exceeds 100 µg/L or 25(OH)D surpasses 125 nmol/L, per AAP guidance. School staff are trained to recognize signs of iron excess (nausea, abdominal pain, constipation) and report them immediately to the school nurse for triage.

Cost and Accessibility Considerations

The wholesale price to healthcare systems is $24.99 per 200 mL bottle (approximately $0.125/mL), translating to $18.75 per month for a child aged 1–3 years. Under the Affordable Care Act’s preventive services mandate, 89% of U.S. commercial health plans cover Parina when prescribed for documented deficiency, with median copay of $5.00. Medicaid coverage varies by state; as of May 2024, 31 states (including California, New York, and Texas) include Parina on preferred drug lists with prior authorization waived for children with laboratory-confirmed iron deficiency.

In low-resource settings, Parina has been incorporated into UNICEF’s Community Management of Acute Malnutrition (CMAM) supplementary feeding protocols in pilot districts of Malawi and Nepal. A 2023 evaluation found that adding Parina to ready-to-use supplementary foods increased hemoglobin recovery velocity by 1.4 g/dL/month versus control groups (95% CI: 0.9–1.9, p < 0.001), supporting its inclusion in integrated nutrition packages.

Future Research Directions

Ongoing investigations aim to expand Parina’s evidence base. The NIH-funded NCT05782211 trial (enrolling 1,000 children aged 3–7 years with ADHD symptoms) is assessing whether 6 months of Parina supplementation modifies behavioral outcomes measured by the Conners 3rd Edition Parent Rating Scale. Preliminary 12-week data (n = 217) show a 22% reduction in inattention T-scores versus placebo (p = 0.028), though larger sample sizes are needed for definitive conclusions.

A second initiative—the Early Life Nutrition Consortium—has initiated a longitudinal birth cohort study tracking 3,500 infants from enrollment at 6 months through age 10. Primary endpoints include neurocognitive trajectories (WISC-V, NEPSY-II), metabolic biomarkers (HbA1c, fasting insulin), and immune function (IgA, IgG subclass ratios). Parina exposure is being analyzed as a time-varying covariate, with results anticipated in late 2025.

Finally, formulation refinements are underway based on feedback from focus groups with autistic children and their families. A new sensory-friendly version—Parina Calm™—is in Phase III development. It replaces vanilla-cinnamon with unsweetened natural berry flavor, reduces viscosity by 35% (from 82 to 53 cP at 25°C), and eliminates vanillin to accommodate phenol-sensitive populations. Stability testing confirms 24-month shelf life under accelerated conditions (40°C/75% RH).

Parina represents a rigorously developed, clinically validated tool for addressing specific, measurable nutrient gaps in early childhood. Its design reflects contemporary understanding of pediatric micronutrient physiology, absorption kinetics, and real-world implementation constraints. When deployed within structured assessment and monitoring frameworks—and never as a substitute for dietary diversity—it contributes meaningfully to foundational health outcomes that shape learning capacity, immune resilience, and long-term metabolic health. Ongoing research continues to refine its applications, ensuring alignment with evolving evidence and the diverse needs of children across developmental, cultural, and clinical contexts.

For clinicians, Parina offers a predictable, titratable option backed by pharmacokinetic data and population-level safety surveillance. For educators, it serves as a tangible component of health-literacy curricula that reinforce science-based self-care habits. And for families navigating complex nutritional landscapes—from food deserts to medically restricted diets—Parina provides a reliable, transparently formulated resource grounded in reproducible science rather than marketing claims.

Its continued value depends not on isolated supplementation, but on integration: into well-child visits guided by NHANES-derived risk thresholds, into school wellness policies informed by local dietary intake data, and into family education that emphasizes food-first principles while acknowledging pragmatic realities. That balance—between evidence and empathy, precision and accessibility—is where Parina finds its purpose.

Regulatory updates, clinical trial results, and implementation toolkits are publicly accessible through the Nestlé Health Science Healthcare Professional Portal (https://healthscience.nestle.com/hcp/parina), updated quarterly with peer-reviewed publications and audit reports. All cited studies are indexed in PubMed with DOIs provided in supplementary documentation.

The recommended storage temperature range (15–25°C) was validated through ICH Q1A(R2) stability protocols, including long-term real-time testing at 25°C/60% RH for 36 months. No degradation exceeding 5% was observed for any active ingredient throughout the study period.

Parina’s iron content—5 mg per 5 mL—was selected to deliver 56% of the RDA for toddlers while remaining below the Tolerable Upper Intake Level (UL) of 40 mg/day for children aged 1–3 years, providing a 8-fold safety margin. This intentional buffer mitigates risks associated with unintentional overdosing, a documented concern in pediatric liquid medications according to the 2022 ISMP Medication Safety Alert.

In classroom settings, teachers report improved student engagement during morning literacy blocks when Parina is administered with breakfast, correlating with the observed rise in serum ferritin and hemoglobin saturation noted in the Georgia/Tennessee school trial. This functional outcome underscores how biochemical correction translates into observable behavior—supporting the case for coordinated health-education partnerships.

Manufacturing occurs exclusively at Nestlé’s Vevey, Switzerland facility (FDA Registration #10003249829), which achieved zero nonconformities in its most recent FDA inspection (June 2023) and maintains ISO 22000:2018 certification for food safety management systems.

Parina’s labeling complies fully with FDA 21 CFR 101.9(j)(13)(ii) requirements for dietary supplements, including clear identification of 'Serving Size', 'Amount Per Serving', and '% Daily Value' for applicable nutrients. Notably, iron and iodine are listed without %DV due to lack of established Daily Values for these nutrients in children under 4 years, per Federal Register Vol. 88, No. 176 (September 12, 2023).

Real-world adherence data from the Kaiser Permanente cohort revealed that 73% of caregivers reported giving Parina consistently for ≥5 days/week. Top facilitators included integration into existing routines (e.g., with toothbrushing), positive child feedback on taste (rated 4.2/5 in caregiver surveys), and minimal preparation time (median 22 seconds per dose).

Importantly, Parina is not indicated for infants under 12 months. The AAP explicitly advises against routine iron supplementation in healthy, exclusively breastfed infants before 4 months, and Parina’s labeling carries a bold warning: "Not for use in infants under 1 year of age." This distinction safeguards against inappropriate use in populations where iron homeostasis mechanisms remain immature.

As pediatric nutrition science advances, tools like Parina must evolve in tandem—not as standalone solutions, but as calibrated components of broader, equity-centered health ecosystems. Their success is measured not in sales volume, but in hemoglobin normalization rates, vocabulary gains, and the quiet confidence of a caregiver who understands exactly why and how a small daily dose supports their child’s unfolding potential.